APA

Sullivan R. J., Infante J. R., Janku F., Wong D. J. L., Sosman J. A., Keedy V., Patel M. R., Shapiro G. I., Mier J. W., Tolcher A. W., Wang-Gillam A., Sznol M., Flaherty K., Buchbinder E., Carvajal R. D., Varghese A. M., Lacouture M. E., Ribas A., Patel S. P., DeCrescenzo G. A., Emery C. M., Groover A. L., Saha S., Varterasian M., Welsch D. J., Hyman D. M. & Li B. T. (20190604). First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study. : Cancer discovery.

Chicago

Sullivan Ryan J, Infante Jeffrey R, Janku Filip, Wong Deborah Jean Lee, Sosman Jeffrey A, Keedy Vicki, Patel Manish R, Shapiro Geoffrey I, Mier James W, Tolcher Anthony W, Wang-Gillam Andrea, Sznol Mario, Flaherty Keith, Buchbinder Elizabeth, Carvajal Richard D, Varghese Anna M, Lacouture Mario E, Ribas Antoni, Patel Sapna P, DeCrescenzo Gary A, Emery Caroline M, Groover Anna L, Saha Saurabh, Varterasian Mary, Welsch Dean J, Hyman David M and Li Bob T. 20190604. First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study. : Cancer discovery.

Harvard

Sullivan R. J., Infante J. R., Janku F., Wong D. J. L., Sosman J. A., Keedy V., Patel M. R., Shapiro G. I., Mier J. W., Tolcher A. W., Wang-Gillam A., Sznol M., Flaherty K., Buchbinder E., Carvajal R. D., Varghese A. M., Lacouture M. E., Ribas A., Patel S. P., DeCrescenzo G. A., Emery C. M., Groover A. L., Saha S., Varterasian M., Welsch D. J., Hyman D. M. and Li B. T. (20190604). First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study. : Cancer discovery.

MLA

Sullivan Ryan J, Infante Jeffrey R, Janku Filip, Wong Deborah Jean Lee, Sosman Jeffrey A, Keedy Vicki, Patel Manish R, Shapiro Geoffrey I, Mier James W, Tolcher Anthony W, Wang-Gillam Andrea, Sznol Mario, Flaherty Keith, Buchbinder Elizabeth, Carvajal Richard D, Varghese Anna M, Lacouture Mario E, Ribas Antoni, Patel Sapna P, DeCrescenzo Gary A, Emery Caroline M, Groover Anna L, Saha Saurabh, Varterasian Mary, Welsch Dean J, Hyman David M and Li Bob T. First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study. : Cancer discovery. 20190604.